South San Francisco, CA, United States of America

Sandip Panicker

USPTO Granted Patents = 22 

 

 

Average Co-Inventor Count = 3.5

ph-index = 8

Forward Citations = 120(Granted Patents)


Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents

Title: Sandip Panicker: Innovator in Complement C1s Antibody Research

Introduction

Sandip Panicker is a notable inventor based in South San Francisco, California, known for his significant contributions to the field of biotechnology. With an impressive repertoire of 19 patents, he has been a driving force in the development of innovative antibody therapies.

Latest Patents

His latest notable patents focus on anti-complement C1s antibodies and their uses. The present disclosures detail antibodies that bind to the complement C1s protein, alongside nucleic acid molecules that encode these antibodies. Some embodiments illustrate how these anti-complement C1s antibodies can inhibit the proteolytic activity of C1s. Furthermore, the disclosures provide compositions containing these antibodies, as well as methods for their production and use.

Career Highlights

Throughout his career, Sandip has worked with prominent biotech companies, notably True North Therapeutics, Inc. and Bioverativ USA Inc. His work at these organizations has contributed to advancements in therapeutic solutions derived from antibody research.

Collaborations

Collaborating with esteemed colleagues such as Graham Parry and Peter Van Vlasselaer, Sandip Panicker has been part of a dynamic network of innovators and researchers, enhancing the knowledge base and practical applications in his field.

Conclusion

In summary, Sandip Panicker showcases a vibrant career marked by innovation in the development of anti-complement C1s antibodies. His ongoing contributions continue to influence biotechnology, emphasizing the importance of his research in creating novel therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…